Ranitidine_HCl_(Form_I_And_Form_Ii)

Category

Ranitidine_HCl_(Form_I_And_Form_Ii)




Useful info

Ranitidine_HCl_(Form_I_And_Form_Ii) Brand names, Ranitidine_HCl_(Form_I_And_Form_Ii) Analogs

Ranitidine_HCl_(Form_I_And_Form_Ii) Brand Names Mixture

  • Tritec (ranitidine bismuth citrate salt)

    • Ranitidine_HCl_(Form_I_And_Form_Ii) Chemical_Formula

    C13H22N4O3S

    Ranitidine_HCl_(Form_I_And_Form_Ii) RX_link

    http://www.rxlist.com/cgi/generic2/ranitbc.htm

    Ranitidine_HCl_(Form_I_And_Form_Ii) fda sheet

    Ranitidine_HCl_(Form_I_And_Form_Ii) FDA

    Ranitidine_HCl_(Form_I_And_Form_Ii) msds (material safety sheet)

    Ranitidine_HCl_(Form_I_And_Form_Ii) MSDS

    Ranitidine_HCl_(Form_I_And_Form_Ii) Synthesis Reference

    B. J. Price et al., U.S. Pat. 4,128,658 (1978)

    Ranitidine_HCl_(Form_I_And_Form_Ii) Molecular Weight

    314.405 g/mol

    Ranitidine_HCl_(Form_I_And_Form_Ii) Melting Point

    69-70 oC

    Ranitidine_HCl_(Form_I_And_Form_Ii) H2O Solubility

    24.7 mg/mL

    Ranitidine_HCl_(Form_I_And_Form_Ii) State

    Solid

    Ranitidine_HCl_(Form_I_And_Form_Ii) LogP

    1.93

    Ranitidine_HCl_(Form_I_And_Form_Ii) Dosage Forms

    Capsule; Liquid; Solution; Tablet; Syrup

    Ranitidine_HCl_(Form_I_And_Form_Ii) Indication

    Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

    Ranitidine_HCl_(Form_I_And_Form_Ii) Pharmacology

    Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.

    Ranitidine_HCl_(Form_I_And_Form_Ii) Absorption

    Approximately 50% bioavailability orally.

    Ranitidine_HCl_(Form_I_And_Form_Ii) Toxicity

    LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.

    Ranitidine_HCl_(Form_I_And_Form_Ii) Patient Information

    PATIENT INFORMATION

    Phenylketonurics: ZANTAC 25 EFFERdose Tablets contain phenylalanine 2.81 mg per 25 mg of ranitidine. ZANTAC 150 EFFERdose Tablets
    contain phenylalanine 16.84 mg per 150 mg of ranitidine. ZANTAC EFFERdose Tablets should not be chewed, swallowed whole, or dissolved
    on the tongue.

    Ranitidine_HCl_(Form_I_And_Form_Ii) Organisms Affected

    Humans and other mammals